Palliative Radiochemotherapie mit Bendamustin bei fortgeschrittenen Tumorrezidiven im HNO-Bereich

Rahn, A.; Schilcher, R. B.; Adamietz, I. A.; Mose, Stephan; Bormeth, S.B.; Böttcher, H.D.

doi:10.1007/pl00002397

Cited by 8 publications

(4 citation statements)

References 17 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a phase II trial, bendamustine has been administered to 14 patients in combination with radiotherapy at a dosage of 100-150 mg/m 2 bendamustine on 2 consecutive days every 4 weeks and 3 Gy given five times per week, up to 15 Gy [27]. A complete remission was achieved in four patients, partial remission was observed in ten patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Promising results with bendamustine and combination with radiotherapy have also been achieved in patients with intensively pretreated recurrent HNC [27].…”

Section: Introductionmentioning

confidence: 92%

Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

et al. 2007

View full text Add to dashboard Cite

show abstract

“…This cytostatic drug has Fig. The cell count is markedly declined after bendamustine application shown acceptable side-effects with myelosuppression as the dose-limiting toxicity [2,3,4,5,6]. The ratio is substantially declined after bendamustine application; b CD4 + lymphocyte count of a female patient with advanced breast cancer before, after two, and after four courses of bendamustine.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to these indications, the drug has shown activity in advanced small cell lung cancer [2] as well as head and neck tumors [3]. In addition to these indications, the drug has shown activity in advanced small cell lung cancer [2] as well as head and neck tumors [3].…”

Section: Introductionmentioning

confidence: 99%

Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer

Klippstein¹,

Schneider²,

Sayer³

et al. 2003

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background: Bendamustine is an alkylator with anticipated antimetabolic activity. It has shown activity in malignant lymphoma, multiple myeloma, and breast cancer. Recognized side-effects are relatively mild with myelosuppression as the dose-limiting toxicity. The CD4/CD8 ratio may be reduced. To what extent the alteration of lymphocytes, especially CD4 + lymphocytes, correlates with an increase in opportunistic infections cannot be definitively answered. Case report: The patient, female, aged 48 years, was suffering from an advanced progressive breast cancer. After initial treatment with several chemotherapies, a cytotoxic therapy was initiated, with bendamustine (150 mg/m 2 ) administered on two consecutive days and repeated every 4 weeks. After five courses, the patient developed Pneumocystis carinii pneumonia (PCP), disclosed in the bronchoalveolar lavage. While receiving bendamustine therapy, the CD4 + and CD8 + lymphocyte counts in the peripheral blood were determined by flow cytometry. The next-to-normal CD4/CD8 ratio before therapy (0,82) had decreased to 0,05 during the therapy mainly due to a decline of CD4 + lymphocyte. The patient was seronegative for human immunodeficiency virus. In spite of high-dose intravenous trimethoprim/sulfamethoxazole and methylprednisolone application, the patient died of a respiratory failure 3 days after PCP was diagnosed. Conclusion: Bendamustine is capable of inducing a reduction in CD4 + lymphocyte counts causing a severe T-lymphocyte-mediated immunosuppression. Measuring CD4 + lymphocyte counts may be helpful in determining the risk of PCP in patients treated with bendamustine.

show abstract

Sensitivity of Human Tumor Cells to Retinoids or Combined Treatment with Retinoids and Ionizing Radiation is not Dependent on RAR-β2 Induction

Blaese

Santo-Hoeltje²,

Rodemann

2003

Strahlenther Onkol

View full text Add to dashboard Cite

The responsiveness of human tumor cells to retinoid treatment alone and particularly to combined treatment with irradiation is not necessarily associated with an induction of RAR-beta2 as it has been postulated so far. Thus, loss of RAR-beta induction in tumors does not seem to be a good prognostic factor for successful retinoid/radiation therapy, since RAR-beta-deficient tumors may also present strong retinoid responsiveness.

show abstract

Palliative Radiochemotherapie mit Bendamustin bei fortgeschrittenen Tumorrezidiven im HNO-Bereich

Abstract: The reported therapy regimen allows successful palliative treatment of intensively pretreated patients with progressive recurrent tumors of the head and neck. Side effects are tolerable even in patients with reduced physical condition.

Cited by 8 publications

References 17 publications

Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer

Sensitivity of Human Tumor Cells to Retinoids or Combined Treatment with Retinoids and Ionizing Radiation is not Dependent on RAR-β2 Induction

Contact Info

Product

Resources

About